CYT 006 AngQb

Drug Profile

CYT 006 AngQb

Alternative Names: Anti-angiotensin II vaccine - Cytos; CYT 006 AngQb Immunodrug™; CYT006-AngQb; Hypertension virus-like particle vaccine - Cytos

Latest Information Update: 27 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytos Biotechnology
  • Class Antihypertensives; Oligopeptides; Vaccines; Virus-like particle vaccines
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 17 Aug 2011 Suspended - Phase-II for Hypertension in Germany (SC)
  • 17 Aug 2011 Suspended - Phase-II for Hypertension in Switzerland (SC)
  • 12 Nov 2009 Cytos Biotechnology updates on the development of the hypertension vaccine CYT 006 AngQb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top